Entinostat(209783-80-2)

Introduction: Entenot is the main candidate product of Syndex Pharmaceutical Company, with the Chinese translation of "Entenot". It has studied and observed the objective tumor response of solid tumors and malignant hematological diseases in 800 cancer patients. Entenort can selectively target the HDAC subtype most relevant to tumor biology, normalize the expression of uncontrolled genes in tumor cells, and thus restore the sensitivity to other targeted therapeutic drugs. Because of its excellent clinical results in breast cancer and lung cancer, entenolt is preparing to carry out a key phase III clinical trial.

Development prospect: Entenot is a novel oral HDAC1 inhibitor, which is safe and effective, whether as a single agent or in combination with commercially available targeted therapeutic drugs, making it different from other HDAC inhibitors. The pre-clinical, phase I and phase II clinical trials completed so far have also confirmed the safety and effectiveness of this product. FDA designated this product as a breakthrough therapeutic drug according to the results of a phase II clinical trial. The phase III clinical trial has also begun, and we are looking forward to the results of the follow-up trial. If we can get the expected results in the phase III clinical trial, we will solve the unmet clinical drug needs, and bring more survival benefits to a large number of patients with advanced breast cancer.

PREVIOUS：Panobinostat(404950-80-7) NEXT：Tucidinostat(1616493-44-7)